More leading oncology companies have outlined their planned highlights for the upcoming annual meeting of the American Society of Clinical Oncology (ASCO).
Japanese pharma major Takeda (TYO: 4502) will present results across a range of cancers, including colorectal, lung, lymphoma, multiple myeloma and leukemia.
Another cancer company, Incyte (Nasdaq: INCY), plans also to provide updates at the European Hematology Association 2024 congress, which will take place in mid-June in Madrid.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze